Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) EBT Margin (2020 - 2025)

Historic EBT Margin for Neuroone Medical Technologies (NMTC) over the last 11 years, with Q4 2025 value amounting to 49.71%.

  • Neuroone Medical Technologies' EBT Margin fell 1042400.0% to 49.71% in Q4 2025 from the same period last year, while for Dec 2025 it was 78.34%, marking a year-over-year increase of 466700.0%. This contributed to the annual value of 39.63% for FY2025, which is 3171100.0% up from last year.
  • Per Neuroone Medical Technologies' latest filing, its EBT Margin stood at 49.71% for Q4 2025, which was down 1042400.0% from 59.08% recorded in Q3 2025.
  • In the past 5 years, Neuroone Medical Technologies' EBT Margin registered a high of 54.53% during Q4 2024, and its lowest value of 13124.54% during Q1 2021.
  • Its 5-year average for EBT Margin is 2945.3%, with a median of 653.18% in 2023.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -55774100bps in 2021, then skyrocketed by 80602800bps in 2023.
  • Quarter analysis of 5 years shows Neuroone Medical Technologies' EBT Margin stood at 8318.94% in 2021, then surged by 82bps to 1512.29% in 2022, then skyrocketed by 77bps to 342.14% in 2023, then skyrocketed by 116bps to 54.53% in 2024, then crashed by -191bps to 49.71% in 2025.
  • Its EBT Margin stands at 49.71% for Q4 2025, versus 59.08% for Q3 2025 and 88.49% for Q2 2025.